Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.12, $0.04 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $113.74 million versus the consensus estimate of $112.89 million.

GUIDANCE:

Ironwood Pharma sees Q4 2023 revenue of $435-450 million, versus the consensus of $438.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.